EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

The effect of mesenchymal stem cells improves the healing of burn wounds: a phase 1 dose-escalation clinical trial

Carl I Schulman iD, Nicholas Namias, Louis Pizano, Luis Rodriguez-Menocal, Divya Aickara, Wellington Guzman, Ambar Candanedo, Eric Maranda, Audrey Beirn, Jeffrey D McBride, Evangelos V Badiavas iD

Scars, Burns & Healing · 2022-01 · 8

DOI: 10.1177/20595131211070783 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Scars, Burns & Healing, online erschienen am 28.06.2022. Verfasst von Carl I Schulman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Ryder Trauma Center, University of Miami School of Medicine, Miami, FL, USA. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stem cell therapy holds promise to improve healing and stimulate tissue regeneration after burn injury. Preclinical evidence has supported this; however, clinical studies are lacking. We examined the application of bone marrow-derived mesenchymal stem cells (BM-MSC) to deep second-degree burn injuries using a two-dose escalation protocol.

Methods

Ten individuals aged 18 years or older with deep second-degree burn wounds were enrolled. The first five patients were administered 2.5 × 10³ BM-MSC/cm 2 to their wounds. After safety of the initial dose level was assessed, a second group of five patients was treated with a higher concentration of 5 × 10³ allogeneic BM-MSC/cm 2 . Safety was assessed clinically and by evaluating cytokine levels in mixed recipient lymphocyte/donor BM-MSC reactions (INFγ, IL-10 and TNFα). At each visit, we performed wound measurements and assessed wounds using a Patient and Observer Scar Assessment Scale (POSAS).

Results

All patients responded well to treatment, with 100% closure of wounds and minimal clinical evidence of fibrosis. No adverse reactions or evidence of rejection were observed for both dose levels. Patients receiving the first dose concentration had a wound closure rate of 3.64 cm 2 /day. Patients receiving the second dose concentration demonstrated a wound closure rate of 10.47 cm 2 /day. The difference in healing rates between the two groups was not found to be statistically significant ( P = 0.17).

Conclusion

BM-MSC appear beneficial in optimising wound healing in patients with deep second-degree burn wounds. Adverse outcomes were not observed when administering multiple doses of allogeneic BM-MSC. Lay Summary Thermal injuries are a significant source of morbidity and mortality, constituting 5%–20% of all injuries and 4% of all deaths. Despite overall improvements in the management of acutely burned patients, morbidities associated with deeper burn injuries remain commonplace. Burn patients are too often left with significant tissue loss, scarring and contractions leading to physical loss of function and long-lasting psychological and emotional impacts. In previous studies, we have demonstrated the safety and efficacy of administering bone marrow-derived mesenchymal stem cells (BM-MSC) to chronic wounds with substantial improvement in healing and evidence of tissue regeneration. In this report, we have examined the application of BM-MSC to deep second-degree burn injuries in patients. The aim of the present phase I/II clinical trial was to examine the safety and efficacy of administering allogeneic BM-MSC to deep second-degree burns. We utilised two different dose levels at concentrations 2.5 × 10 3 and 5 × 10 3 cells/cm 2 . Patients with deep second-degree burn wounds up to 20% of the total body surface area were eligible for treatment. Allogeneic BM-MSC were applied to burn wounds topically or by injection under transparent film dressing

Schlagwörter

Stichwörter der Autor:innen

Second-degree burnbone marrow–derived mesenchymal stem cellsburn scarcell therapythermal injurywound healing

Autor:innen und Institutionen

  • Department of Surgery, Ryder Trauma Center, University of Miami School of Medicine, Miami, FL, USA.
  • Department of Dermatology and Cutaneous Surgery, Leonard M Miller School of Medicine, University of Miami, Interdisciplinary Stem Cell Institute, Miami, FL, USA.

ORCID-Profile: Carl I Schulman, Evangelos V Badiavas

Förderung

  • U.S. Department of Defense

Zitieren

APA

Schulman, C. I., Namias, N., Pizano, L., Rodriguez-Menocal, L., Aickara, D., Guzman, W., Candanedo, A., Maranda, E., Beirn, A., McBride, J. D., & Badiavas, E. V. (2022). The effect of mesenchymal stem cells improves the healing of burn wounds: a phase 1 dose-escalation clinical trial. Scars, Burns & Healing, 8. https://doi.org/10.1177/20595131211070783

Vancouver

Schulman CI, Namias N, Pizano L, Rodriguez-Menocal L, Aickara D, Guzman W, et al. The effect of mesenchymal stem cells improves the healing of burn wounds: a phase 1 dose-escalation clinical trial. Scars, Burns & Healing. 2022;8. doi:10.1177/20595131211070783

BibTeX
@article{Schulman2022,
  author = {Schulman, Carl I and Namias, Nicholas and Pizano, Louis and Rodriguez-Menocal, Luis and Aickara, Divya and Guzman, Wellington and Candanedo, Ambar and Maranda, Eric and Beirn, Audrey and McBride, Jeffrey D and Badiavas, Evangelos V},
  title = {The effect of mesenchymal stem cells improves the healing of burn wounds: a phase 1 dose-escalation clinical trial},
  journal = {Scars, Burns & Healing},
  year = {2022},
  volume = {8},
  doi = {10.1177/20595131211070783}
}
Kostenlos starten →